After prior announcements to rationalize its Consumer Healthcare portfolio and focus on several priority brands and categories, Sanofi has now divested two OTC brands to Italy’s Angelini. Both brands are marketed in Germany and Austria as pharmacy only medicines—BoxaGrippal (ibuprofen/pseudoephedrine) cold and flu brand and the Heumann range of medicinal teas indicated to treat a number of complaints including stress and abdominal pain. HBW covers how this sale was likely the last deal sanctioned by Sanofi’s recently departed CEO Olivier Brandicourt and shares recent statement by Novartis’ Paul Hudson who has been announced as Brandicourt’s replacement.